Entera Bio Ltd. – NASDAQ:ENTX

Entera Bio Ltd. stock price today

$1.92
-0.22
-10.7%
Financial Health
0
1
2
3
4
5
6
7
8
9

Entera Bio Ltd. stock price monthly change

+13.16%
month

Entera Bio Ltd. stock price quarterly change

+13.16%
quarter

Entera Bio Ltd. stock price yearly change

+241.27%
year

Entera Bio Ltd. key metrics

Market Cap
77.38M
Enterprise value
13.70M
P/E
-2.31
EV/Sales
55.72
EV/EBITDA
2.13
Price/Sales
105.39
Price/Book
2.20
PEG ratio
-0.39
EPS
-0.28
Revenue
N/A
EBITDA
-8.69M
Income
-8.71M
Revenue Q/Q
N/A
Revenue Y/Y
6690.90%
Profit margin
2480.49%
Oper. margin
-8191.87%
Gross margin
23.58%
EBIT margin
-8191.87%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Entera Bio Ltd. stock price history

Entera Bio Ltd. stock forecast

Entera Bio Ltd. financial statements

Entera Bio Ltd. (NASDAQ:ENTX): Profit margin
Jun 2023 0 -2.32M
Sep 2023 0 -2.37M
Dec 2023 4.48M -1.99M -44.51%
Mar 2024 0 -2.01M
Entera Bio Ltd. (NASDAQ:ENTX): Analyst Estimates
Mar 2024 0 -2.01M
Sep 2025 0 -4.45M
Oct 2025 0 -5.51M
Dec 2025 0 -7.34M
  • Analysts Price target

  • Financials & Ratios estimates

Entera Bio Ltd. (NASDAQ:ENTX): Earnings per share (EPS)
2023-03-27 -0.11 0.21
Entera Bio Ltd. (NASDAQ:ENTX): Debt to assets
Jun 2023 10445000 2.21M 21.19%
Sep 2023 8565000 2.32M 27.19%
Dec 2023 11765000 1.37M 11.72%
Mar 2024 10239000 1.37M 13.44%
Entera Bio Ltd. (NASDAQ:ENTX): Cash Flow
Jun 2023 -1.55M -1K 5K
Sep 2023 -1.52M 185 -77
Dec 2023 -2.50M -4.78K 6.03M
Mar 2024 -1.86M 0 29.99K

Entera Bio Ltd. alternative data

Entera Bio Ltd. (NASDAQ:ENTX): Employee count
Aug 2023 18
Sep 2023 19
Oct 2023 19
Nov 2023 19
Dec 2023 19
Jan 2024 19
Feb 2024 19
Mar 2024 17
Apr 2024 17
May 2024 17
Jun 2024 17
Jul 2024 17

Entera Bio Ltd. other data

0.08% -10.51%
of ENTX is owned by hedge funds
22.00K -3.02M
shares is hold by hedge funds

Entera Bio Ltd. (NASDAQ:ENTX): Insider trades (number of shares)
Period Buy Sel
Apr 2023 30000 0
Aug 2023 78000 0
Dec 2023 95808 0
Jan 2024 24730 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
TAITEL HAYA director
Ordinary Shares, par value NIS 0.0000769 per share 9,500 $0.99 $9,405
Purchase
TAITEL HAYA director
Ordinary Shares, par value NIS 0.0000769 per share 15,230 $0.77 $11,727
Purchase
TOLEDANO MIRANDA JAYNE director, officer: Chief Execut..
Ordinary Shares, par value NIS 0.0000769 per share 23,952 $0.71 $17,006
Purchase
TOLEDANO MIRANDA JAYNE director, officer: Chief Execut..
Warrants (right to buy) 23,952 $1 $23,952
Purchase
LIEBERMAN GERALD M director
Ordinary Shares, par value NIS 0.0000769 per share 23,952 $0.71 $17,006
Purchase
LIEBERMAN GERALD M director
Warrants (right to buy) 23,952 $1 $23,952
Purchase
TAITEL HAYA director
Ordinary Shares, par value NIS 0.0000769 per share 18,000 $0.62 $11,214
Purchase
ELLIS SEAN director
Ordinary Shares, par value NIS 0.0000769 per share 40,000 $0.6 $24,000
Purchase
LIEBERMAN GERALD M director
Ordinary Shares, par value NIS 0.0000769 per share 20,000 $0.59 $11,780
Purchase
TOLEDANO MIRANDA JAYNE director, officer: Chief Execut..
Ordinary Shares, par value NIS 0.0000769 per share 30,000 $1.01 $30,300
Patent
Application
Filling date: 31 Jan 2022 Issue date: 19 May 2022
Application
Filling date: 23 Dec 2019 Issue date: 7 May 2020
Grant
Filling date: 9 Feb 2016 Issue date: 10 Mar 2020
Application
Filling date: 21 Aug 2019 Issue date: 19 Dec 2019
Grant
Filling date: 6 Jun 2018 Issue date: 24 Sep 2019
Insider Compensation
Dr. Phillip Schwartz Ph.D. (1962) Executive Vice President, Pres of R&D and Director
$441,000
Dr. Hillel Galitzer (1978) Chief Operating Officer
$359,000
Dr. Arthur C. Santora II, M.D., Ph.D. (1951) Chief Medical Officer
$355,000
Friday, 8 November 2024
zacks.com
globenewswire.com
Thursday, 26 September 2024
zacks.com
Wednesday, 25 September 2024
globenewswire.com
Wednesday, 18 September 2024
zacks.com
Monday, 2 September 2024
zacks.com
Tuesday, 20 August 2024
globenewswire.com
Thursday, 15 August 2024
zacks.com
Friday, 9 August 2024
globenewswire.com
Tuesday, 23 July 2024
investorplace.com
Monday, 8 July 2024
investorplace.com
Tuesday, 2 July 2024
investorplace.com
Tuesday, 25 June 2024
investorplace.com
Thursday, 20 June 2024
investorplace.com
investorplace.com
Monday, 17 June 2024
investorplace.com
Monday, 10 June 2024
investorplace.com
Friday, 7 June 2024
investorplace.com
Monday, 3 June 2024
zacks.com
Thursday, 23 May 2024
investorplace.com
Thursday, 16 May 2024
zacks.com
Wednesday, 15 May 2024
globenewswire.com
Monday, 13 May 2024
GlobeNewsWire
Friday, 26 April 2024
Zacks Investment Research
Thursday, 18 April 2024
Zacks Investment Research
Monday, 15 April 2024
InvestorPlace
Friday, 12 April 2024
Zacks Investment Research
Tuesday, 9 April 2024
Zacks Investment Research
Tuesday, 30 January 2024
GlobeNewsWire
Wednesday, 16 August 2023
GlobeNewsWire
  • What's the price of Entera Bio Ltd. stock today?

    One share of Entera Bio Ltd. stock can currently be purchased for approximately $1.92.

  • When is Entera Bio Ltd.'s next earnings date?

    Unfortunately, Entera Bio Ltd.'s (ENTX) next earnings date is currently unknown.

  • Does Entera Bio Ltd. pay dividends?

    No, Entera Bio Ltd. does not pay dividends.

  • How much money does Entera Bio Ltd. make?

    Entera Bio Ltd. has a market capitalization of 77.38M. Entera Bio Ltd. made a loss 8.89M US dollars in net income (profit) last year or $0.21 on an earnings per share basis.

  • What is Entera Bio Ltd.'s stock symbol?

    Entera Bio Ltd. is traded on the NASDAQ under the ticker symbol "ENTX".

  • What is Entera Bio Ltd.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Entera Bio Ltd.?

    Shares of Entera Bio Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Entera Bio Ltd.'s key executives?

    Entera Bio Ltd.'s management team includes the following people:

    • Dr. Phillip Schwartz Ph.D. Executive Vice President, Pres of R&D and Director(age: 63, pay: $441,000)
    • Dr. Hillel Galitzer Chief Operating Officer(age: 47, pay: $359,000)
    • Dr. Arthur C. Santora II, M.D., Ph.D. Chief Medical Officer(age: 74, pay: $355,000)
  • How many employees does Entera Bio Ltd. have?

    As Jul 2024, Entera Bio Ltd. employs 17 workers.

  • When Entera Bio Ltd. went public?

    Entera Bio Ltd. is publicly traded company for more then 7 years since IPO on 28 Jun 2018.

  • What is Entera Bio Ltd.'s official website?

    The official website for Entera Bio Ltd. is enterabio.com.

  • How can i contact Entera Bio Ltd.?

    Entera Bio Ltd. can be reached via phone at +972 2 532 7151.

Entera Bio Ltd. company profile:

Entera Bio Ltd.

enterabio.com
Exchange:

NASDAQ

Full time employees:

17

Industry:

Biotechnology

Sector:

Healthcare

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Kiryat Hadassah Minrav Building
Jerusalem, 9112002

CIK: 0001638097
ISIN: IL0011429839
CUSIP: M40527109